fbpx

Weekly Top News – Psoriasis – October 7, 2019

October 7, 2019

Stelara (ustekinumab) / J&J
Janssen submits application to U.S. FDA seeking approval of Stelara (ustekinumab) for the treatment of pediatric patients with moderate to severe plaque psoriasis (PRNewswire) – Oct 7, 2019 – “The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric (ages 6-11) patients with moderate to severe plaque psoriasis (PsO)….The STELARA sBLA is based on results from the Phase 3 CADMUS Jr study…”

Tremfya (guselkumab) / J&J; Taltz (ixekizumab) / Eli Lilly
New head-to-head data show Taltz (ixekizumab) superiority versus Tremfya (guselkumab) in people with moderate to severe plaque psoriasis (PRNewswire) – Oct 3, 2019 – P4, N=1,027; IXORA-R (NCT03573323); Sponsor: Eli Lilly and Company; “Eli Lilly and Company…today presented detailed data at the 5th Annual Maui Derm NP+PA Fall meeting from the Phase 4 IXORA-R study, the first head-to-head (H2H) study…using the Psoriasis Area Severity Index (PASI) 100 score as the primary endpoint. Taltz met the primary endpoint of superiority vs. TREMFYA in the proportion of patients with moderate to severe plaque psoriasis achieving complete skin clearance…as well as key secondary endpoints. The study is ongoing through Week 24….Lilly plans to share results on the remaining key secondary endpoint of proportion of patients achieving PASI 100 at 24 weeks in 2020.”

 

ANB019 / AnaptysBio
AnaptysBio reports positive topline data from interim analysis of GALLOP phase 2 clinical trial of ANB019 monotherapy in moderate to severe generalized pustular psoriasis (AnaptysBio Press Release) – Sep 30, 2019 – P2, N=10; GALLOP (NCT03619902); Sponsor: AnaptysBio, Inc; “AnaptysBio…today announced positive topline data from an interim analysis of its Phase 2 clinical trial of ANB019 in moderate-to-severe generalized pustular psoriasis (GPP) patients, also known as the GALLOP trial. Enrollment is ongoing and AnaptysBio anticipates additional clinical data and a regulatory strategy update for the development of ANB019 in GPP during 2020…ANB019 was generally well-tolerated and no serious or severe adverse events were reported in this interim analysis.”

 

Otezla (apremilast) / Amgen
Otezla sales projection: $1.9B in 2019 and $2.2B in 2020 (Cowen & Co) – Sep 30, 2019 – A subscription to Thomson ONE is required to gain full access to report 67971845; Page no: 2914; REPORT TITLE: “Therapeutic categories outlook”; AUTHOR: Cowen Health Care Research, et al; DATE: 09/17/2019

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Skyrizi US sales estimate: $81M (consensus: $65M) in Q3 2019; Skyrizi US sales projection: $243M (consensus: $205M) in FY2019 (UBS) – Oct 2, 2019 – A subscription to Thomson ONE is required to gain full access to report 68016563; Page no: 1; REPORT TITLE: “US Pharmaceuticals “UBS healthcare expert symposium: Dermatology panel key …””; AUTHOR: Jacob, Navin, et al; DATE: 09/26/2019

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Skyrizi revenue projection: Guidance of $150M in H2 2019 (Zacks) – Oct 2, 2019 – A subscription to Thomson ONE is required to gain full access to report 67978057; Page no: 5; REPORT TITLE: “AbbVie Inc.(ABBV) Zacks company report”; AUTHOR: Research Department; DATE: 09/18/2019

 

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Skyrizi US sales estimate: $86M (consensus: $65M) in Q3 2019; Skyrizi US sales projection: $263M (consensus: $205M) in FY2019 (UBS) – Oct 5, 2019 – A subscription to Thomson ONE is required to gain full access to report 68021393; Page no: 1; REPORT TITLE: “US Pharmaceuticals “New product launch tracker””; AUTHOR: Jacob, Navin, et al; DATE: 09/27/2019

 

BMS-986165 / BMS
BMS-986165 sales projection: Consensus of $3.5B peak (Exane BNP Paribas) – Oct 4, 2019 – A subscription to Thomson ONE is required to gain full access to report 67972680; Page no: 38; REPORT TITLE: “Pharmaceuticals: Champions League 2019: Powered by pulse “; AUTHOR: Hector, Luisa, et al; DATE: 09/17/2019

 

Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
Ilumya sales projection: $120M peak (Credit Suisse) – Oct 4, 2019 – A subscription to Thomson ONE is required to gain full access to report 68021370; Page no: 4; REPORT TITLE: “India Pharma Sector – Quick take – Ilumya volume trend not encouraging; Aurobindo gained 47% share in Makena; Uloric exclusivity sees lower competition”; AUTHOR: Aggarwal, Anubhav, et al; DATE: 09/27/2019

No Comments

Post a Comment

Comment
Name
Email
Website